# Multiple Myeloma trials: 389 new since Nov 2024

Updated November 9, 2026.

389 clinical studies in Multiple Myeloma were first posted on ClinicalTrials.gov from November 15, 2024 to November 9, 2026; 112 have an industry sponsor and 343 are recruiting or about to. The newest, NCT07927023, was posted on November 9, 2026: A Study to Learn About a Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple Myeloma (Pfizer).

## The full list

New Multiple Myeloma clinical trials: 389 rows for $19.45, first posted on ClinicalTrials.gov from November 12, 2024 to November 9, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Enrollment, Enrollment type, Location countries, Central contact, Contact phone, Contact email, Last update posted, Read on, Source. The new rows each week by email, about 16 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (central contact, contact phone, contact email, sponsor class, condition groups (MeSH), interventions and 5 more), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/condition/multiple-myeloma

SpecStream is the live web data engine for teams and agents. It reads every new study on ClinicalTrials.gov each morning, and this page is that reading. Ask for the conditions, phases or countries you follow and each new trial arrives in your sheet, CRM, Slack or agent with the sponsor, the sites and the listed contact.

- New trials: 389
- Industry sponsored: 112
- Recruiting or not yet: 343
- Latest posted: November 9, 2026

## Newest trials

The newest 100 of 389, each linked to its record. The full list holds every one with the sponsor class, interventions, start date and the central contact as the record prints it.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Countries | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 9, 2026 | NCT07927023 | A Study to Learn About a Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple Myeloma | Pfizer | Observational | Not yet recruiting | Multiple Myeloma | 1 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07927023) |
| November 3, 2026 | NCT07914556 | Phase 1 Study of 6MW5311 in Adults With Relapsed or Refractory Blood Cancers | Mabwell (Shanghai) Bioscience Co., Ltd. | Phase 1 | Recruiting | AML, Multiple Myeloma, CMML | 122 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07914556) |
| November 3, 2026 | NCT07912684 | The Value of a Tailored-based, Exercise Program for Improving Quality of Life of Patients With Hematologic Malignancies: a Pilot Randomized... | Gruppo Italiano Malattie EMatologiche dell'Adulto | Not applicable | Recruiting | Acute Myeloid Leukemia, Multiple Myeloma, Lymphoma | 75 | Italy | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07912684) |
| November 3, 2026 | NCT07911748 | A Study of MBS314 for Injection in Participants With Relapsed/Refractory Multiple Myeloma. | Beijing Mabworks Biotech Co., Ltd. | Phase 1/2 | Not yet recruiting | Multiple Myeloma | 78 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07911748) |
| November 2, 2026 | NCT07910903 | Study of CM336+CM313 Combination Therapy in Patients With Relapsed or Refractory Multiple Myeloma | Keymed Biosciences Co.Ltd | Phase 3 | Not yet recruiting | Multiple Myeloma (MM) | 320 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07910903) |
| October 30, 2026 | NCT07907211 | Aspirin vs. Rivaroxaban for Thromboprophylaxis in Multiple Myeloma | Chen Lijuan | Phase 4 | Recruiting | Multiple Myeloma, Venous Thromboembolism (VTE) | 200 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07907211) |
| October 30, 2026 | NCT07906418 | BCMA Polymorphisms in Patients With Multiple Myeloma | Başakşehir Çam & Sakura City Hospital | Observational | Not yet recruiting | Multiple Myeloma | 420 | Turkey (Türkiye) | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07906418) |
| October 29, 2026 | NCT07903636 | QLS4131 for Relapsed/Refractory Multiple Myeloma With Extramedullary Disease | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 | Not yet recruiting | Multiple Myeloma (MM) | 55 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07903636) |
| October 29, 2026 | NCT07903506 | To Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma | Kite, A Gilead Company | Phase 3 | Not yet recruiting | Newly Diagnosed Multiple Myeloma | 750 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07903506) |
| October 29, 2026 | NCT07903272 | A Trial Comparing Ramantamig and Daratumumab (Ramantamig-D) Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Participants... | Janssen Research & Development, LLC | Phase 3 | Not yet recruiting | Multiple Myeloma | 1,000 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07903272) |
| October 28, 2026 | NCT07901868 | Elranatamab With Mezigdomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma | PETHEMA Foundation | Phase 2 | Not yet recruiting | Multiple Myeloma Refractory, Multiple Myeloma in Relapse | 60 | Spain | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07901868) |
| October 26, 2026 | NCT07895017 | Time-limited Treatment With Avatrombopag Pre- and Post-CAR T-cell Therapy to Prevent Post-CAR T-cell Cytopenias | University of Virginia | Phase 2 | Not yet recruiting | Thrombocytopenia | 26 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07895017) |
| October 23, 2026 | NCT07891871 | RE-RITE: Real-world Evaluation of Response, Implementation and Toxicity of Elranatamab | The Royal Wolverhampton Hospitals NHS Trust | Observational | Not yet recruiting | Myeloma Multiple | 400 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07891871) |
| October 22, 2026 | NCT07887984 | Comparing Bispecific Antibody Treatment to Autologous Stem Cell Transplant for Newly Diagnosed, Standard Risk Multiple Myeloma | Alliance for Clinical Trials in Oncology | Phase 2/3 | Not yet recruiting | Multiple Myeloma (MM) | 920 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07887984) |
| October 21, 2026 | NCT07887672 | A Trial to Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Standard of Care in Newly Diagnosed Multiple Myeloma | Kite, A Gilead Company | Phase 3 | Not yet recruiting | Newly Diagnosed Multiple Myeloma | 600 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07887672) |
| October 20, 2026 | NCT07882069 | Effect of ACTIVE-Care on Cancer-Related Fatigue, Hope, and Psychological Resilience in Adolescents With Acute Lymphoblastic Leukemia | Selcuk University | Not applicable | Completed | Cancer (Colon Cancer, Breast Cancer, Lymphoma, Chronic Lymphoma Leukemia, Multiple Myeloma), Adolescent, Resilience... | 70 | Turkey (Türkiye) | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07882069) |
| October 19, 2026 | NCT07881835 | A Phase IV Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma That is Not Responding to Four or... | Pfizer | Phase 4 | Not yet recruiting | Relapsed/Refractory Multiple Myeloma, Multiple Myeloma | 75 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07881835) |
| October 14, 2026 | NCT07874334 | Phase 1a/b Study of GPRC5D CART Therapy in Relapsed/Refractory Multiple Myeloma and Light-chain Amyloidosis | Hadassah Medical Organization | Phase 1 | Not yet recruiting | Relapsed/Refractory Multiple Myeloma (RRMM), Light-Chain Amyloidosis | 160 | Israel | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07874334) |
| October 13, 2026 | NCT07871747 | Microbiome Intervention for CAR-T Optimization and Response (MICRO-CART) | University of Chicago | Phase 1 | Not yet recruiting | Lymphoma, B-Cell, Multiple Myeloma | 32 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07871747) |
| October 2, 2026 | NCT07855718 | Serum Soluble BCMA as a Non-Invasive Marker in Multiple Myeloma | Assiut University | Observational | Not yet recruiting | Multiple Myeloma | 90 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07855718) |
| October 1, 2026 | NCT07851493 | Exercise Phenotyping Prior to Chemotherapy in Newly Diagnosed Multiple Myeloma (MM-Exercise) | Technical University of Munich | Observational | Recruiting | Exercise Behavior, Multiple Myeloma | 80 | Germany | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07851493) |
| September 30, 2026 | NCT07850284 | SMS-Based Remote Symptom Monitoring for Patients With Plasma Cell Disorders | Mayo Clinic | Observational | Recruiting | AL Amyloidosis, Multiple Myeloma | 150 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07850284) |
| September 30, 2026 | NCT07848672 | Early Prophylactic rhTPO Administration for Thrombocytopenia Associated With EAP Regimen-Based Hematopoietic Stem Cell Mobilization | The Affiliated People's Hospital of Ningbo University | Phase 2/3 | Not yet recruiting | Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, Hematopoietic Stem Cell Mobilization... | 70 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07848672) |
| September 25, 2026 | NCT07842198 | Restrictive Versus Standard Antibiotic Treatment During CAR-T Therapy | Zealand University Hospital | Phase 2 | Not yet recruiting | Large B-Cell Lymphoma (LBCL), Multiple Myeloma (MM), Gut Microbiota | 150 | Denmark | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07842198) |
| September 22, 2026 | NCT07833046 | Long-term Follow-up Study in Subjects With Multiple Myeloma Previously Treated With GC012F Injection | RenJi Hospital | Observational | Enrolling by invitation | Multiple Myeloma | 40 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07833046) |
| September 21, 2026 | NCT07831122 | Study of Belantamab Mafodotin, Cevostamab, Pomalidomide for RRMM Patients (MAPLE) | Canadian Myeloma Research Group | Phase 1 | Not yet recruiting | Relapsed Refractory Multiple Myeloma (RRMM) | 108 | Canada | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07831122) |
| September 21, 2026 | NCT07830485 | CM336 Plus Daratumumab and Lenalidomide in Transplant-Ineligible Newly Diagnosed Multiple Myeloma | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 | Not yet recruiting | Multiple Myeloma | 24 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07830485) |
| September 18, 2026 | NCT07828522 | F182112 in Combination With Isatuximab and Lenalidomide for the Treatment of Patients With Newly Diagnosed Multiple Myeloma | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 | Not yet recruiting | Multiple Myeloma (MM), Transplant-eligible Patients | 10 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07828522) |
| September 17, 2026 | NCT07825064 | Cevostamab in Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CAR T-Cell Therapy in Participants With Previously... | Hoffmann-La Roche | Phase 2 | Recruiting | Multiple Myeloma | 45 | Germany | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07825064) |
| September 17, 2026 | NCT07823959 | CBC-Based Inflammatory Indices in Newly Diagnosed Multiple Myeloma | Assiut University | Observational | Not yet recruiting | Multiple Myeloma | 60 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07823959) |
| September 10, 2026 | NCT07814170 | A Manualised Post-Traumatic Growth Intervention For People With Hematological Cancers In Greece | University of West Attica | Not applicable | Active not recruiting | Blood Cancers, Leukemia, Lymphoma, Bone Marrow Transplant, Psychological Trauma, Neoplasms, Hematological Malignancies... | 80 | Greece | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07814170) |
| September 10, 2026 | NCT07811986 | HP-001 Plus Dexamethasone for Relapsed/Refractory Multiple Myeloma With Extramedullary Disease | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 | Not yet recruiting | Multiple Myeloma (MM) | 20 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07811986) |
| September 9, 2026 | NCT07809594 | CS1-Targeted CAR-T Cells for Relapsed/Refractory Multiple Myeloma | Institute of Hematology & Blood Diseases Hospital, China | Phase 1 | Active not recruiting | Relapsed/Refractory Multiple Myeloma (RRMM), Plasma Cell Myeloma | 10 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07809594) |
| August 27, 2026 | NCT07789522 | Safety and Efficacy of Elranatamab Plus Isatuximab, Bortezomib, and Lenalidomide in Ultra-High-Risk Multiple Myeloma | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 | Not yet recruiting | Multiple Myeloma (MM) | 15 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07789522) |
| August 25, 2026 | NCT07785505 | Musculoskeletal Ultrasound in Patients With Hematologic Malignancies | Assiut University | Observational | Not yet recruiting | Hematologic Neoplasms, Leukemia, Lymphoma, Multiple Myeloma, Musculoskeletal Diseases | 50 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07785505) |
| August 25, 2026 | NCT07783607 | MM-CARE: Cardiovascular Risk Assessment in Adults With Multiple Myeloma | University of Vermont Medical Center | Not applicable | Not yet recruiting | Multiple Myeloma, Heart Disease Risk Factors | 33 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07783607) |
| August 24, 2026 | NCT07782944 | CD38 Targeted -PET/ CT for Multiple Myeloma | Guilin Medical University, China | Not applicable | Recruiting | Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma | 100 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07782944) |
| August 20, 2026 | NCT07777406 | Real-life Study on the Use of Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Relapsed/Refractory Multiple Myeloma | Università degli Studi 'G. d'Annunzio' Chieti e Pescara | Observational | Recruiting | Plasma Cell Neoplasms | 60 | Italy | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07777406) |
| August 20, 2026 | NCT07776964 | Monitoring for CardioToxicity Using WeArable deVices While Undergoing cancEr Treatments (MCT-WAVE) | University of Minnesota | Not applicable | Not yet recruiting | Cardiotoxicity, Cancer, Cardiac Arrhythmia, Left Ventricular Dysfunction, Breast Cancer, Multiple Myeloma | 72 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07776964) |
| August 19, 2026 | NCT07774988 | Individualized Education for Bortezomib-Related Symptom Management in Multiple Myeloma | Can Lafci | Not applicable | Completed | Multiple Myeloma | 49 | Turkey (Türkiye) | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07774988) |
| August 18, 2026 | NCT07771361 | BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma and Multiple Myeloma | Luminary Therapeutics | Phase 2 | Not yet recruiting | Non-Hodgkin Lymphoma Refractory/ Relapsed, Multiple Myeloma Refractory, Multiple Myeloma in Relapse, Non-Hodgkin... | 90 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07771361) |
| August 14, 2026 | NCT07764978 | Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT | AstraZeneca | Phase 3 | Recruiting | Newly Diagnosed Multiple Myeloma | 750 | Australia, Brazil, Canada, Denmark, France, Germany, Italy, Japan, Poland... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07764978) |
| August 14, 2026 | NCT07764861 | A Open-Label Phase in Participants With Multiple Myeloma | Innovent Biologics (Suzhou) Co. Ltd. | Phase 2 | Not yet recruiting | Multiple Myeloma | 120 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07764861) |
| August 13, 2026 | NCT07763054 | Low-dose Liposomal Amphotericin B for Antifungal Prophylaxis in Prolonged Neutropenia Patients | Haikou Affiliated Hospital of Central South University Xiangya School of Medicine | Observational | Recruiting | Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, Lymphoma, Multiple Myeloma, Chronic... | 30 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07763054) |
| August 12, 2026 | NCT07760454 | A Clinical Study of CT0596 CAR-T in Relapsed/Refractory Multiple Myeloma | UCARsgen Biotech Limited | Phase 1/2 | Recruiting | Relapsed/Refractory Multiple Myeloma | 68 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07760454) |
| August 12, 2026 | NCT07759102 | Allogeneic ORCA-Q Stem Cell Transplant for the Treatment of Relapsed and Refractory High Risk Multiple Myeloma | University of California, Davis | Phase 1 | Not yet recruiting | Recurrent Multiple Myeloma, Refractory Multiple Myeloma | 20 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07759102) |
| August 11, 2026 | NCT07757412 | Teclistamab in Combination With Pomalidomide Administered in Alternative Fashion in Participants With Relapsed or Refractory Multiple... | Odense University Hospital | Phase 2 | Not yet recruiting | Multiple Myeloma Progression | 50 | Denmark, Estonia, Finland, Norway | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07757412) |
| August 7, 2026 | NCT07751783 | Development and Dissemination of Exercise Prescription and Intervention for Cancer Populations | Kaohsiung Medical University Chung-Ho Memorial Hospital | Not applicable | Recruiting | Cancer, Cancer (Colon Cancer, Breast Cancer, Lymphoma, Chronic Lymphoma Leukemia, Multiple Myeloma), Lung Cancer... | 150 | Taiwan | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07751783) |
| August 6, 2026 | NCT07748689 | Comparing Lower Versus Standard Doses of Belantamab Mafodotin With Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple... | Polish Myeloma Consortium | Phase 2 | Not yet recruiting | Relapsed / Refractory Multiple Myeloma | 228 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07748689) |
| August 4, 2026 | NCT07746232 | Validating DW-MRI and Fat Fraction in Multiple Myeloma Post-ASCT: The RAC-FAT Study" | Fondazione EMN Italy Onlus | Observational | Not yet recruiting | Multiple Myeloma (MM) | 92 | Italy | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07746232) |
| August 3, 2026 | NCT07742527 | A Study to Evaluate the Subcutaneous Belantamab (BCMAb) Formulation Versus Intravenous Belantamab in Participants With Multiple Myeloma... | GlaxoSmithKline | Phase 1 | Not yet recruiting | Multiple Myeloma | 22 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07742527) |
| August 3, 2026 | NCT07742215 | A Study of the Efficacy and Safety of BCD-248 in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma... | Biocad | Phase 3 | Recruiting | Myeloma Multiple | 390 | Belarus, Russia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07742215) |
| July 31, 2026 | NCT07740486 | A Study Comparing Treatment With Teclistamab and Talquetamab Versus Daratumumab and Lenalidomide in Patients With Multiple Myeloma After... | Polish Myeloma Consortium | Phase 3 | Not yet recruiting | Multiple Myeloma (MM) | 248 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07740486) |
| July 31, 2026 | NCT07740317 | Neurocognitive Trajectories After BCMA CAR-T | Wake Forest University Health Sciences | Observational | Recruiting | Multiple Myeloma (MM), CART Therapy, Refractory Multiple Myeloma (RRMM) | 50 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07740317) |
| July 30, 2026 | NCT07735637 | A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed... | AstraZeneca | Phase 3 | Recruiting | Newly Diagnosed Multiple Myeloma (NDMM) | 750 | Australia, Brazil, Canada, China, Denmark, France, Germany, Italy, Japan... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07735637) |
| July 30, 2026 | NCT07735546 | A Phase 1 Study of UB-VV500 With Rapamycin in Relapsed/Refractory Multiple Myeloma | Umoja Biopharma | Phase 1 | Not yet recruiting | Multiple Myeloma in Relapse, Multiple Myeloma (MM) | 100 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07735546) |
| July 29, 2026 | NCT07732712 | Isa-VRdlite for of Frail and/or Much Older Patients With High Risk Newly Diagnosed Multiple Myeloma Base on Circulating Plasma Cells | The Affiliated People's Hospital of Ningbo University | Phase 2/3 | Not yet recruiting | Multiple Myeloma | 15 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07732712) |
| July 27, 2026 | NCT07728188 | A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies... | AbbVie | Phase 3 | Not yet recruiting | Relapsed or Refractory Multiple Myeloma | 520 | Australia, Canada, France, Germany, Hungary, Italy, Netherlands, Norway... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07728188) |
| July 27, 2026 | NCT07727668 | Iberdomide (CC-220) Priming to Improve T Cell Fitness Prior to Leukapheresis for Chimeric Antigen Receptor T Cell (CAR-T) Therapy for... | Shambavi Richard | Early phase 1 | Not yet recruiting | Multiple Myeloma, Relapsed/Refractory Multiple Myeloma | 22 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07727668) |
| July 24, 2026 | NCT07726160 | A Study of KIV-318 Injection in Patients With BCMA-Positive Relapsed/Refractory Multiple Myeloma | Institute of Hematology & Blood Diseases Hospital, China | Phase 1 | Not yet recruiting | Relapse and/or Refractory Multiple Myeloma | 30 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07726160) |
| July 24, 2026 | NCT07725406 | Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma | Weill Medical College of Cornell University | Phase 1 | Recruiting | Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed or Refractory Multiple Myeloma (MM) | 32 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07725406) |
| July 23, 2026 | NCT07721350 | Prospective Evaluation of Subcutaneous Administration of Daratumumab by the FreedomEDGE® Infusion System | Hospices Civils de Lyon | Not applicable | Not yet recruiting | Multiple Myeloma or Amyloidosis | 100 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07721350) |
| July 22, 2026 | NCT07720843 | TAlquetamab and BeLantamab Mafodotin in Relapsed/Refractory Multiple Myeloma (TaBleMM) | Montefiore Medical Center | Phase 1 | Not yet recruiting | Relapse Multiple Myeloma, Refractory Multiple Myeloma | 50 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07720843) |
| July 20, 2026 | NCT07715630 | In Vivo PICX CAR-T Therapy for R/R Multiple Myeloma | Chongqing Precision Biotech Co., Ltd | Phase 1 | Recruiting | Relapsed or Refractory Multiple Myeloma (RRMM) | 15 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07715630) |
| July 20, 2026 | NCT07713511 | INfections in Patients Treated With CAR-T | IRCCS Azienda Ospedaliero-Universitaria di Bologna | Observational | Not yet recruiting | Relapsed Multiple Myeloma, Refractory Multiple Myeloma, B-Cell Non-Hodgkin Lymphoma, Bloodstream Infections, CAR-T Cell... | 290 | Italy | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07713511) |
| July 15, 2026 | NCT07705074 | FAPI PET Imaging - An Exploratory Study | Martin Huellner | Phase 1/2 | Not yet recruiting | Thyroid Pathology, Head and Neck Cancer (H&N), Sinonasal Tract Tumor, Sarcoidosis, Thyroid Cancer, Breast Cancer... | 770 | Switzerland | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07705074) |
| July 10, 2026 | NCT07695740 | Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma | Excyte Biopharma Ltd | Phase 2 | Not yet recruiting | Relapsed or Refractory Multiple Myeloma (RRMM) | 64 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07695740) |
| July 8, 2026 | NCT07691034 | Monitoring MRD in Multiple Myeloma in Serum by Mass Spectrometry | Odense University Hospital | Observational | Not yet recruiting | Multiple Myeloma, Minimal Residual Disease | 40 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07691034) |
| July 8, 2026 | NCT07689058 | CAR-T in Relapsed/Refractory Multiple Myeloma | Dr. Zaineb Akram | Phase 2 | Recruiting | Multiple Myeloma Refractory, Multiple Myeloma in Relapse | 10 | Pakistan | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07689058) |
| July 7, 2026 | NCT07689006 | Real-World Clinical Outcomes in Relapsed/Refractory Multiple Myeloma Treated With Pomalidomide Regimens | Bristol-Myers Squibb | Observational | Completed | Relapsed/Refractory Multiple Myeloma | 341 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07689006) |
| July 7, 2026 | NCT07687004 | Sonrotoclax and BCMA Bispecific Antibody in Newly Diagnosed Systemic AL Amyloidosis Based on t(11;14) Genetic Stratification | Institute of Hematology & Blood Diseases Hospital, China | Phase 1/2 | Not yet recruiting | Multiple Myeloma (MM) | 50 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07687004) |
| July 6, 2026 | NCT07684274 | Early Screening for Multiple Myeloma Based on Liquid Biopsy cfDNA Fragmentomics | The First Affiliated Hospital with Nanjing Medical University | Observational | Not yet recruiting | Multiple Myeloma (MM), Smoldering Multiple Myeloma (SMM), MGUS | 290 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07684274) |
| July 2, 2026 | NCT07681596 | A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma | AstraZeneca | Phase 1/2 | Recruiting | Relapsed or Refractory Multiple Myeloma | 101 | Australia, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07681596) |
| July 1, 2026 | NCT07679919 | BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Hematologic Malignancies | Luminary Therapeutics | Phase 1 | Not yet recruiting | Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Hairy Cell Leukemia, Multiple Myeloma | 27 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07679919) |
| June 29, 2026 | NCT07674498 | Immune Fitness in Older Patients With Relapsed and Refractory Multiple Myeloma | Jules Bordet Institute | Not applicable | Recruiting | Myeloma Multiple | 31 | Belgium | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07674498) |
| June 26, 2026 | NCT07671287 | GMMG-HD11/DSMM XXI/64007957MMY3010 | University of Heidelberg Medical Center | Phase 3 | Not yet recruiting | Multiple Myeloma | 399 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07671287) |
| June 25, 2026 | NCT07667868 | A Phase I, Open-label, Multicenter Study to Evaluate the Safety and Tolerability of BP2202 in Patients With Relapsed/Refractory Multiple... | BrightPath Biotherapeutics Co., Ltd. | Phase 1 | Not yet recruiting | Relapsed/Refractory Multiple Myeloma (RRMM) | 18 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07667868) |
| June 24, 2026 | NCT07665450 | A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide... | Janssen Research & Development, LLC | Phase 3 | Recruiting | Multiple Myeloma | 1,000 | Australia, Czechia, France, Germany, Greece, Israel, Italy, Netherlands... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07665450) |
| June 24, 2026 | NCT07665307 | Delayed Toxicities Post-CAR-T | Icahn School of Medicine at Mount Sinai | Observational | Recruiting | Multiple Myeloma | 30 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07665307) |
| June 23, 2026 | NCT07663253 | Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients | Shanghai Zhongshan Hospital | Observational | Recruiting | Multiple Myeloma | 333 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07663253) |
| June 22, 2026 | NCT07660939 | GPRC5D Targeted PET/CT Imaging in Plasma Cell Disorders | Peking University First Hospital | Phase 1 | Recruiting | Plasma Cell Disorders, Multiple Myeloma (MM) | 50 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07660939) |
| June 18, 2026 | NCT07657312 | Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory... | Naresh Bumma | Phase 2 | Recruiting | Cytokine Release Syndrome, Recurrent Multiple Myeloma, Refractory Multiple Myeloma | 35 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07657312) |
| June 17, 2026 | NCT07652281 | A Clinical Study of SHR-5421 in Patients With Multiple Myeloma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 1 | Recruiting | Multiple Myeloma | 97 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07652281) |
| June 16, 2026 | NCT07649681 | Gustabor Phase 2 - Treating Taste Changes During Cancer Therapy: A Randomized Study Evaluating an AI- Based Nutrition Intervention | Wuerzburg University Hospital | Not applicable | Recruiting | Multiple Myeloma (MM), GI Cancer, Taste Disorder, Melanoma (Skin Cancer), Urogenital Cancers | 198 | Germany | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07649681) |
| June 16, 2026 | NCT07649525 | Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level | University of Leeds | Phase 3 | Recruiting | Multiple Myeloma (MM), Plasma Cell Leukemia (PCL) | 1,226 | United Kingdom | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07649525) |
| June 15, 2026 | NCT07648459 | CM336-SOC for Dynamically High-Risk Multiple Myeloma Study | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 | Not yet recruiting | Multiple Myeloma | 46 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07648459) |
| June 15, 2026 | NCT07648264 | Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting... | CSL Behring | Phase 3 | Recruiting | Secondary Immune Deficiency | 63 | Belgium, Canada, Czechia, Denmark, France, Germany, Italy, Poland, Spain... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07648264) |
| June 15, 2026 | NCT07646873 | PET-Enabled Dual-Energy CT in Multiple Myeloma | University of California, Davis | Not applicable | Not yet recruiting | Multiple Myeloma (MM) | 45 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07646873) |
| June 11, 2026 | NCT07642362 | Digital Support for Multiple Myeloma Quality of Life | CareAcross | Not applicable | Recruiting | Multiple Myeloma, Patient Reported Outcome (PRO), Supportive Care in Cancer, Quality of Life | 108 | Greece | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07642362) |
| June 10, 2026 | NCT07638683 | A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple... | Shanghai Zhongshan Hospital | Phase 2 | Recruiting | Multiple Myeloma, AL Amyloidosis | 30 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07638683) |
| June 10, 2026 | NCT07637578 | A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma | SCRI Development Innovations, LLC | Phase 2 | Recruiting | Multiple Myeloma (MM), Multiple Myeloma Refractory, Multiple Myeloma in Relapse, Multiple Myeloma | 46 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07637578) |
| June 8, 2026 | NCT07634263 | Why Patients Decline or Are Being Deemed Ineligible to Receive Home-based Treatment: a Mixed Methods Study | Odense University Hospital | Observational | Not yet recruiting | Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, Multiple Myeloma Progression, Multiple... | 50 | Denmark | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07634263) |
| June 5, 2026 | NCT07628595 | Safety and Efficacy of RN9101 in the Treatment of Relapsed/Refractory Multiple Myeloma | The First Affiliated Hospital with Nanjing Medical University | Early phase 1 | Not yet recruiting | Multiple Myeloma (MM) | 19 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07628595) |
| June 3, 2026 | NCT07624760 | Early Detection of Amyloidosis in Monoclonal Gammopathy Using Nuclear Medicine Imaging | University of Zurich | Not applicable | Not yet recruiting | Monoclonal Gammopathy, Monoclonal Gammopathy of Undetermined Significance (MGUS), Multiple Myeloma, AL Amyloidosis... | 50 | Switzerland | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07624760) |
| June 3, 2026 | NCT07624513 | D2 - Isa-Iber-VD Induction, Followed by Risk & Response Adapted Consolidation & Maintenance, in Transplant-Eligible NDMM | Dana-Farber Cancer Institute | Phase 3 | Recruiting | Multiple Myeloma | 720 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07624513) |
| June 3, 2026 | NCT07623798 | A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003 | Innovent Biologics (Suzhou) Co. Ltd. | Phase 3 | Recruiting | Relapsed or Refractory Multiple Myeloma | 255 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07623798) |
| June 2, 2026 | NCT07620275 | Safety and Efficacy of KSVCBD Injection in Multiple Myeloma Expressing CD19 and/or BCMA | Chinese PLA General Hospital | Phase 1 | Recruiting | Multiple Myeloma | 9 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07620275) |
| May 29, 2026 | NCT07614360 | Study of Alternative and Approved Dosing Regimens of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With... | GlaxoSmithKline | Phase 2 | Not yet recruiting | Multiple Myeloma | 150 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07614360) |
| May 29, 2026 | NCT07614243 | Long Non-coding RNA (lncRNA) ZFAS1-Mediated Mechanism of Roasted Nux Vomica in Intervening Bortezomib-Induced Peripheral Neuropathy | The First Affiliated Hospital of Zhejiang Chinese Medical University | Not applicable | Completed | Multiple Myeloma, Chemotherapy-Induced Peripheral Neuropathy | 22 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07614243) |
| May 29, 2026 | NCT07612787 | A Multicenter Study of Belantamab Mafodotin and Mezigdomide in Patients With Relapsed Multiple Myeloma | Centre Hospitalier Universitaire de Saint Etienne | Phase 1/2 | Not yet recruiting | Myeloma Multiple | 44 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07612787) |

## Sponsors posting most

| Sponsor | New trials | Latest |
| --- | --- | --- |
| Institute of Hematology & Blood Diseases Hospital, China | 25 | October 29, 2026 |
| GlaxoSmithKline | 12 | August 3, 2026 |
| Janssen Research & Development, LLC | 8 | October 29, 2026 |
| AbbVie | 6 | July 27, 2026 |
| Memorial Sloan Kettering Cancer Center | 6 | March 6, 2026 |
| Xuzhou Medical University | 6 | July 17, 2025 |
| Mayo Clinic | 5 | September 30, 2026 |
| AstraZeneca | 5 | August 14, 2026 |
| National Cancer Institute (NCI) | 5 | March 30, 2026 |
| Gruppo Italiano Malattie EMatologiche dell'Adulto | 4 | November 3, 2026 |
| Odense University Hospital | 4 | August 11, 2026 |
| IRCCS Azienda Ospedaliero-Universitaria di Bologna | 4 | July 20, 2026 |
| The First Affiliated Hospital with Nanjing Medical University | 4 | July 6, 2026 |
| Regeneron Pharmaceuticals | 4 | May 27, 2026 |
| Qilu Pharmaceutical Co., Ltd. | 4 | February 10, 2026 |
| Medical College of Wisconsin | 4 | November 19, 2025 |
| Washington University School of Medicine | 4 | November 12, 2025 |
| The First Affiliated Hospital of Soochow University | 4 | June 12, 2025 |
| Pfizer | 3 | November 9, 2026 |
| Assiut University | 3 | October 2, 2026 |

## By phase

| Phase | New trials | Latest |
| --- | --- | --- |
| [Not applicable](https://specstream.ai/data/clinical-trials/phase/not-applicable) | 71 | November 3, 2026 |
| [Phase 2](https://specstream.ai/data/clinical-trials/phase/phase-2) | 67 | October 29, 2026 |
| [Phase 1](https://specstream.ai/data/clinical-trials/phase/phase-1) | 65 | November 3, 2026 |
| [Observational](https://specstream.ai/data/clinical-trials/phase/observational) | 64 | November 9, 2026 |
| [Phase 1/2](https://specstream.ai/data/clinical-trials/phase/phase-1-2) | 41 | November 3, 2026 |
| [Phase 3](https://specstream.ai/data/clinical-trials/phase/phase-3) | 37 | November 2, 2026 |
| [Early phase 1](https://specstream.ai/data/clinical-trials/phase/early-phase-1) | 25 | July 27, 2026 |
| [Phase 4](https://specstream.ai/data/clinical-trials/phase/phase-4) | 11 | October 30, 2026 |
| [Phase 2/3](https://specstream.ai/data/clinical-trials/phase/phase-2-3) | 8 | October 22, 2026 |

## By country

| Country | New trials | Latest |
| --- | --- | --- |
| [China](https://specstream.ai/data/clinical-trials/country/china) | 116 | November 3, 2026 |
| [United States](https://specstream.ai/data/clinical-trials/country/united-states) | 114 | October 26, 2026 |
| [France](https://specstream.ai/data/clinical-trials/country/france) | 34 | August 14, 2026 |
| [Italy](https://specstream.ai/data/clinical-trials/country/italy) | 32 | November 3, 2026 |
| [Germany](https://specstream.ai/data/clinical-trials/country/germany) | 28 | October 1, 2026 |
| [Spain](https://specstream.ai/data/clinical-trials/country/spain) | 26 | October 28, 2026 |
| [Australia](https://specstream.ai/data/clinical-trials/country/australia) | 25 | August 14, 2026 |
| [Canada](https://specstream.ai/data/clinical-trials/country/canada) | 20 | September 21, 2026 |
| [South Korea](https://specstream.ai/data/clinical-trials/country/south-korea) | 18 | August 14, 2026 |
| [Japan](https://specstream.ai/data/clinical-trials/country/japan) | 17 | August 14, 2026 |
| [United Kingdom](https://specstream.ai/data/clinical-trials/country/united-kingdom) | 16 | August 14, 2026 |
| [Greece](https://specstream.ai/data/clinical-trials/country/greece) | 15 | September 10, 2026 |
| [Poland](https://specstream.ai/data/clinical-trials/country/poland) | 15 | August 14, 2026 |
| [Norway](https://specstream.ai/data/clinical-trials/country/norway) | 15 | August 11, 2026 |
| [Israel](https://specstream.ai/data/clinical-trials/country/israel) | 13 | October 14, 2026 |
| [Brazil](https://specstream.ai/data/clinical-trials/country/brazil) | 12 | August 14, 2026 |
| [Denmark](https://specstream.ai/data/clinical-trials/country/denmark) | 11 | September 25, 2026 |
| [Netherlands](https://specstream.ai/data/clinical-trials/country/netherlands) | 11 | July 27, 2026 |
| [Taiwan](https://specstream.ai/data/clinical-trials/country/taiwan) | 10 | August 14, 2026 |
| [Turkey (Türkiye)](https://specstream.ai/data/clinical-trials/country/turkey-t-rkiye) | 8 | October 30, 2026 |
| [Sweden](https://specstream.ai/data/clinical-trials/country/sweden) | 8 | August 14, 2026 |
| [Belgium](https://specstream.ai/data/clinical-trials/country/belgium) | 6 | June 29, 2026 |
| [Czechia](https://specstream.ai/data/clinical-trials/country/czechia) | 6 | June 24, 2026 |
| [Portugal](https://specstream.ai/data/clinical-trials/country/portugal) | 5 | July 27, 2026 |
| [Switzerland](https://specstream.ai/data/clinical-trials/country/switzerland) | 4 | July 15, 2026 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Condition groups are the MeSH terms ClinicalTrials.gov assigns to each study's conditions; a study with several is in several groups. Sponsor class is the register's class of the lead sponsor. The central contact is in the full list only as the record prints it.

Free to reuse with credit to SpecStream under [CC BY 4.0](https://creativecommons.org/licenses/by/4.0/).